Top Page
Zotefoams
(LSE:ZTF)
Zotefoams (ZTF) vs. iShares MSCI United Kingdom ETF (EWC)
Zotefoams Business Overview & Revenue Model
Zotefoams Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 147.79M | 126.97M | 127.37M | 100.75M | 82.65M |
| Gross Profit | 46.13M | 41.05M | 38.73M | 26.57M | 27.78M |
| EBITDA | 12.28M | 23.41M | 22.16M | 15.67M | 15.72M |
| Net Income | -2.75M | 9.24M | 10.01M | 4.38M | 7.16M |
Balance Sheet | |||||
| Total Assets | 174.75M | 175.61M | 170.36M | 159.38M | 158.22M |
| Cash, Cash Equivalents and Short-Term Investments | 10.53M | 6.29M | 10.59M | 8.05M | 8.50M |
| Total Debt | 43.56M | 37.86M | 38.41M | 42.40M | 44.10M |
| Total Liabilities | 65.39M | 59.85M | 60.82M | 61.60M | 63.85M |
| Stockholders Equity | 109.36M | 115.76M | 109.54M | 97.78M | 94.38M |
Cash Flow | |||||
| Free Cash Flow | 11.35M | -702.00K | 14.03M | 3.83M | -1.85M |
| Operating Cash Flow | 25.00M | 7.78M | 21.12M | 10.90M | 10.86M |
| Investing Cash Flow | -13.34M | -8.29M | -7.09M | -6.98M | -12.71M |
| Financing Cash Flow | -7.41M | -3.73M | -11.53M | -4.34M | 3.72M |
Zotefoams Technical Analysis
Zotefoams Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | £690.59M | 23.25 | 6.65% | 7.50% | 4.75% | -3.29% | |
68 Neutral | £2.95B | 8.31 | 15.96% | 4.64% | -15.51% | 200.70% | |
67 Neutral | £312.16M | 26.57 | 4.26% | 2.11% | -4.39% | 33.44% | |
64 Neutral | £162.95M | 14.46 | -2.45% | 1.13% | 16.39% | -129.71% | |
62 Neutral | £965.30M | ― | -5.93% | 1.53% | 0.71% | -274.39% | |
50 Neutral | £181.88M | ― | -6.25% | ― | 0.81% | 15.63% | |
43 Neutral | AU$1.38B | -6.07 | -40.62% | 4.17% | -4.78% | -42.91% |
Zotefoams Corporate Events
Zotefoams plc announced that directors and persons discharging managerial responsibilities have acquired shares under the company’s Share Incentive Plan. This transaction, involving the purchase of partnership shares and allocation of matching shares, reflects the company’s commitment to aligning management interests with shareholder value, potentially impacting its market positioning and stakeholder confidence.
Zotefoams plc announced that its directors and persons discharging managerial responsibilities have acquired ordinary shares under the company’s Share Incentive Plan. This transaction, involving the purchase of dividend shares, reflects the company’s ongoing commitment to align the interests of its leadership with those of its shareholders, potentially impacting its market positioning and stakeholder confidence.
At its 2025 Annual General Meeting, Zotefoams plc successfully passed all resolutions, including ordinary and special resolutions, with a shareholder voting turnout of 53.51%. The approval of these resolutions, including the re-election of directors and authorization of share allotments, reflects strong shareholder support and positions the company for continued strategic growth and operational efficiency.
Zotefoams has reported a strong trading performance for the first four months of 2025, achieving an 8% sales growth and record revenue of £50.7 million. The company is executing a refreshed strategy, including restructuring its commercial function and expanding its manufacturing footprint in Vietnam, which is strategically important due to the concentration of the global athletic footwear market in Asia. Despite potential challenges from US tariffs, Zotefoams remains confident in its growth prospects, supported by robust margins, a growing order book, and strategic investments in North America and Asia.
Zotefoams plc announced that its directors and persons discharging managerial responsibilities have acquired shares under the company’s Share Incentive Plan. This acquisition, involving the purchase of partnership shares and allocation of matching shares, reflects the company’s commitment to aligning management interests with shareholder value, potentially strengthening its market position and stakeholder confidence.
Zotefoams plc announced the exercise of nil cost options by Group CFO Gary McGrath under the Deferred Bonus Share Plan, involving 2,125 ordinary shares at a price of £2.53 each. This transaction, reflecting dividends during the restricted period, aligns with the UK Market Abuse Regulation, potentially impacting shareholder value and executive compensation strategies.
Zotefoams plc announced the appointment of Nick Wright as the new Group Chief Financial Officer, effective by October 2025, succeeding Gary McGrath. Nick Wright brings over 20 years of experience in financial management and transformation, which aligns with Zotefoams’ strategic growth ambitions. His expertise in the manufacturing sector and listed company transformation will support Zotefoams’ next phase of growth, as expressed by Group CEO Ronan Cox.
Zotefoams plc announced the granting of share awards to its Executive Directors and Persons Discharging Managerial Responsibilities under the Long Term Incentive Plan 2017 and the Deferred Bonus Share Plan 2017. The awards, which include performance and restricted shares, are subject to vesting and holding periods, aligning with the company’s strategic goals and regulatory requirements. This move is part of Zotefoams’ efforts to incentivize key personnel and align their interests with the company’s long-term performance, potentially impacting its market positioning and stakeholder engagement.
Zotefoams plc has released its 2024 Annual Report and announced the 2025 Annual General Meeting. The report, prepared in compliance with UK-adopted international accounting standards, includes financial statements, a review of business performance, and details of principal risks and uncertainties. The announcement underscores Zotefoams’ commitment to transparency and provides stakeholders with a comprehensive view of the company’s financial health and strategic direction.
Zotefoams plc has announced the conditional issuance of 400,000 new ordinary shares to its Employee Benefit Trust to support future share incentive schemes. This move, pending approval, will result in the company having a total of 49,246,234 ordinary shares in issue, impacting the voting rights calculations for shareholders. Admission of these shares to the London Stock Exchange is expected on April 22, 2025, marking a strategic step in enhancing employee engagement and aligning with shareholder interests.
Zotefoams plc announced that directors and persons discharging managerial responsibilities have acquired shares under the company’s Share Incentive Plan. The shares were purchased at £2.504 each, with additional matching shares allocated at no cost. This move aligns with regulatory requirements and reflects the company’s commitment to aligning management interests with shareholder value.
Zotefoams plc announced that its directors and persons discharging managerial responsibilities (PDMRs) have acquired ordinary shares in the company. The transactions, which took place on April 9 and 10, 2025, involved the Group CFO, G C McGrath, acquiring 15,948 shares at £2.3200 per share, and the Group CEO, R M Cox, acquiring 8,008 shares at £2.4972 per share. This announcement is in compliance with the UK Market Abuse Regulation, reflecting the company’s commitment to transparency and regulatory adherence.
Zotefoams PLC has announced a change in its major holdings, with BlackRock, Inc. adjusting its voting rights to below 5%. This shift in shareholding could influence Zotefoams’ strategic decisions and stakeholder dynamics, reflecting BlackRock’s investment strategy and potentially impacting the company’s market positioning.
Zotefoams announced that Lynn Drummond, its Non-Executive Director and Chair, has been appointed as a Non-Executive Director of PUMA AIM VCT plc, which was listed on the London Stock Exchange’s main market. This move is part of the company’s ongoing strategic positioning within the industry and may influence its governance and market perception.